DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) announced that the European Patent Office recently issued Patent No. 3687513, titled “Treatment of Fragile X Syndrome and Autism with Cannabidiol,” which includes claims directed to methods of treating one or more behavioral symptoms of Fragile X syndrome and methods of treating one or more behavioral symptoms of autism spectrum disorder by transdermally administering a therapeutically effective amount of cannabidiol (CBD).
This new patent, which expires in 2038, is part of an expanding international intellectual property portfolio covering the Company’s transdermal cannabidiol product candidate, Zygel™ CBD gel. There are currently five corresponding U.S. patents related to methods of treating Fragile X syndrome or autism spectrum disorder.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News.
Thanks for visiting! Looking for some Chester County pride? We got you covered! Shop our MyChesCo store and show your love for Chester County, Pennsylvania. We got shirts, hats, and more – all with a unique ChesCo flair. Plus, proceeds from each purchase helps support our mission of bringing reliable information and resources to the people of Chester County.